Want to see ECIA full AI Analyst Report?
ECIA Stock Chart & Stats
$0.14
$0.03(7.14%)
At close: 4:00 PM EST
$0.14
$0.03(7.14%)
Day’s Range― - ―
52-Week Range$0.03 - $0.40
Previous CloseN/A
Volume5.10K
Average Volume (3M)16.18K
Market Cap
$762.96K
Enterprise Value$1.42
Total Cash (Recent Filing)$170.76K
Total Debt (Recent Filing)$1.56M
Price to Earnings (P/E)―
Beta23.29
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding16,879,644
10 Day Avg. Volume10,380
30 Day Avg. Volume16,177
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)1.35
Price to Sales (P/S)0.33
P/FCF Ratio-4.53
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Usage-driven Recurring RevenueThe business sells disposable single-use components consumed per procedure, creating a usage-driven recurring revenue stream tied to surgical volumes. This model supports predictable repeat demand and scales with procedure growth, underpinning durable revenue potential.
Differentiated Safety TechnologyEncision’s core technology targets stray electrosurgical currents, a clear safety differentiation. Safety-focused product features create clinical procurement stickiness and higher adoption hurdles for competitors, supporting sustained demand in minimally invasive surgery markets.
Strong Unit Economics And Capital CushionA ~47% gross margin indicates healthy unit economics that can absorb variable costs and support profitability as volumes improve. Positive shareholders' equity provides a capital buffer to manage near-term volatility while pursuing operational improvements.
Bears Say
Persistent Revenue DeclineRevenue contraction (~8% decline) has persisted, reducing gross profit dollars and scale. Sustained top-line decline impairs absorption of fixed costs, limits reinvestment capacity, and makes restoring profitability harder without market-share or volume recovery.
Negative Operating And Free Cash FlowBoth operating and free cash flow are negative, indicating the business is not self-funding. Continued cash burn raises reliance on external financing, which can dilute shareholders, increase financing costs, and restrict investment in sales and product development.
Rising Leverage And Poor ReturnsDebt has risen versus declining equity (debt ~1.19x equity) and ROE is deeply negative (~-50%). Higher leverage with persistent losses heightens solvency risk, limits strategic flexibility, and increases the urgency of restoring profitable operations.
Encision News
ECIA FAQ
What was Encision Inc’s price range in the past 12 months?
Encision Inc lowest stock price was $0.03 and its highest was $0.40 in the past 12 months.
What is Encision Inc’s market cap?
Encision Inc’s market cap is $762.96K.
When is Encision Inc’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Encision Inc’s earnings last quarter?
Currently, no data Available
Is Encision Inc overvalued?
According to Wall Street analysts Encision Inc’s price is currently Overvalued.
Does Encision Inc pay dividends?
Encision Inc does not currently pay dividends.
What is Encision Inc’s EPS estimate?
Encision Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Encision Inc have?
Encision Inc has 16,879,644 shares outstanding.
What happened to Encision Inc’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Encision Inc?
Currently, no hedge funds are holding shares in ECIA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Encision Inc
Encision Inc. (ECIA), established in 1991 and headquartered in Boulder, Colorado, operates as a medical device firm specializing in the development, manufacturing, and commercialization of proprietary surgical instruments for the U.S. market. The company's core offering revolves around its patented Active Electrode Monitoring (AEM) technology, featured in both surgical instruments and dedicated monitors. This innovative system significantly enhances patient safety and optimizes outcomes during laparoscopic surgical procedures. Encision's AEM instrument portfolio encompasses a diverse array of endo-mechanical tools, such as scissors, graspers, and dissectors, alongside specialized fixed-tip and suction-irrigation electrodes. Beyond these, the company supplies specialized handles designed for complex laparoscopic operations, characterized by their robust shafts and ergonomic designs. They also provide the AEM EndoShield 2 burn protection systems. Complementing these instruments, Encision markets its AEM monitor product line, essential for use in conjunction with its AEM instruments. Distribution of Encision's products occurs through a hybrid sales model, leveraging both direct company representatives and an established network of independent sales agents.
Technical Analysis
Ownership Overview
53.49% Insiders
6.29% Other Institutional Investors
40.21% Public Companies and
Individual Investors